A Tale of Two Subcutaneous Engineered Coagulation Factors



Howard Levy Chief Medical Officer Catalyst Biosciences


Boston, MA - 21 August 2019



The Catalyst Biosciences subcutaneous solution



catalystbiosciences.com




Our highly potent candidates:

- + Quick & simple SQ injection
- + Self-administered
- + Ideal for pediatric patients
- Achieve higher & more stable factor levels
- + Continuously at protective levels

Subcutaneous pharmacokinetics are complex

Absorption of subcutaneous injection

- + Creation of a depot at the injection site
- Local catabolism at the injection site decreases bioavailability +
- + Prolongation of observed half-life because of depot returning drug to circulation via Lymphatic and Venous systems
 - Slow subcutis convection and diffusion to Lymphatic and Venous capillaries results in absorption rate-limited PK and prolonged systemic exposure
 - GAG and negative charge barrier
 - SQ absorption of protein may be slow with Tmax up to 8 days in humans
 - Large proteins (>20 kDa) are mainly transported by Lymphatics
 - Transport in the Lymphatics is unlikely to be the rate-limiting step for the slow absorption after SQ injection



Subcutaneous pharmacokinetics are complex

FIX subcutaneous pharmacokinetics


- Extravascular distribution and collagen IV binding further impact factor IX PK +
 - Decreases observed bioavailability
 - Later release contributes to prolonged observed half-life
- Competition for binding sites with CRIM positive FIX +

FVIIa subcutaneous pharmacokinetics

+ Rapid absorption from compared with FIX


Redosing any agent within 3 half-lives results in accumulation of plasma levels





Marzeptacog alfa (activated): MarzAA rFVIIa


SQ prophylaxis and SQ treatment of a bleed are clear unmet needs in hemophilia and other bleeding disorders



Orphan Drug Designation in the US and EU

catalystbiosciences.com






- + Four engineered amino acid substitutions within the FVIIa protein
- + 9-fold more potent catalytic activity than NovoSeven RT
- + Allows subcutaneous dosing
- + Half-life prolonged when using subcutaneous dosing

Subcutaneous Prophylaxis: Hemophilia A or B with inhibitors




MarzAA phase 2/3 SQ clinical trial MAA-201 design



- Patients with documented annual bleeding rate (ABR) >12
- Open label SQ study with individual dose + escalation if needed in Hemophilia A or B with inhibitors


- +




+ Primary endpoint: reduction in annualized bleed rate at final dose level

Secondary endpoints: safety and tolerability, inhibitor formation

MarzAA PK IV 18 µg/kg then SQ 30 µg/kg







- + IV half-life of 3.65 hours
- + SQ half-life of 17 hours
- + Stable levels after SQ dosing for 48 hours without high peak after IV dosing


60

MarzAA SQ PK demonstrates prolonged half-life


SQ half-life increased to 17.0 hours from an IV half-life of 3.65 hours

Route	Half-life alpha (hr)	Half-life beta (hr)	Mean Residence Time (hr)	Cmax (ng/mL)	Tmax (hr)	AUC _{0-t} (ng/mL*hr)	AUC _{0-inf} (ng/mL*hr)	Bioavailability
IV Mean ± SEM	1.47 ± 0.29	3.65 ± 0.23	4.05 ± 0.39	375 ± 54	0.5 ± 0.4	1076 ± 97	1102 ± 101	27 ± 6%
SQ Mean ± SEM		17.0 ± 3.1	25.8 ± 4.5	24 ± 4.5	7 ± 0.8	473 ± 132	609 ± 190	






MarzAA: Robust reduction in annualized bleed rate (ABR)




catalystbiosciences.com




Significant reduction in Proportion of Days with Bleeding (PDB)

Median Proportion of Days with Bleeding reduced to zero




Orange denotes the Proportion of Days with Bleeding during period of observation

- Average pre-treatment proportion of days of bleeding was 12.3% (SD 5.8%) [median = 11.0%] +
- Average **on-treatment** proportion was reduced to **0.8%** (SD 0.9%) [median 0%] +
- Analysis of these pairwise differences by Wilcoxon signed-rank test has p=0.009 for 93.8% reduction




Marzeptacog alfa (activated) Phase 2: Clinical efficacy 7 of 9 subjects had no bleeding (spontaneous or traumatic) at final dose level Greater than 90% reduction in all bleeding; Median ABR zero; Median bleeding days zero Mean Annualized Bleeding Rates (ABR) significantly reduced from 19.8 to 1.6 Mean Proportion of Days with Bleeding (PDB) significantly reduced from 12.3% to 0.8%




catalystbiosciences.com










6 m pre-treatment

On treatment

MAA-201 safety

Safe & well tolerated No anti-drug antibodies were detected

- One fatal unrelated SAE: intracerebral hemorrhage due to untreated hypertension +
- 517 SQ injections were administered +
 - 6 injection site reactions in 2 subjects
 - 1 moderate swelling that resolved without sequelae in one subject +
 - + 2 mild and 3 moderate redness that resolved without sequelae in the other subject and did not occur with subsequent SQ injections




The Potential for Subcutaneous Treatment of a Bleed




Preclinical evaluation of bleeding in hemophilia mice

Acute injury model with SQ dosing *after* the injury

SQ dosing one minute after injury



Acute injury model with SQ dosing prior to injury





Preclinical hemophilia A mouse model

- + **Standardized** bleeding models are used to evaluate efficacy of hemostatic agents
- Represents a **traumatic** injury
- The standard acute injury model is IV treatment of the agent 5 min prior to injury to the tail that induces bleeding
- **Two approaches** to evaluate SQ MarzAA in a hemophilia A mouse model
 - + SQ treatment *prior* to injury
 - + SQ treatment *after* injury

Fast onset of action for SQ MarzAA in Hemophilia A mice

Acute mouse injury model with dosing *prior* to injury







SQ MarzAA normalizes bleeding

- + **SQ treatment** of MarzAA 15 min prior to injury normalizes bleeding
- Normalization of bleeding demonstrated +at comparable SQ and IV doses
- Clear dose dependent effect +
- Fast onset of action +
- These doses translate to the range of +**doses** (μ g/kg) being explored in clinical trials

SQ MarzAA reduces bleeding when dosed After the Injury

Acute mouse injury model with dosing after the injury






Reduced bleeding *After* Injury


- + Hemophilic mice bleed **considerably more** than normal mice
- + SQ treatment of MarzAA one min after traumatic bleeding has started significantly reduces blood loss and stops the bleed
- + The effect is **dose dependent**
- Reduction in blood loss is similar to IV
 NovoSeven

Thrombogenicity risk can be evaluated in vitro

The thrombin generation assay is an effective model of coagulation









Potential to treat break through bleeds in patients on Hemlibra

MarzAA has a preferred coagulation profile that is similar to NovoSeven



catalystbiosciences.com



- MarzAA and NovoSeven behave similarly when combined with Hemlibra
- MarzAA could allow hemophilia A patients to combine two SQ therapies - "sports prophylaxis" or treat breakthrough bleeds
 - MarzAA works well at plasma levels + achievable with SQ dosing
- Normal Response
- Hemophilia Response

Data supports SQ MarzAA for treatment of a bleed


SQ MarzAA rapidly reaches therapeutic concentrations in humans

SQ MarzAA reduces bleeding *before* and *after* an injury in preclinical models

Thrombin generation for MarzAA + Hemlibra is similar to NovoSeven + Hemlibra *in vitro*

catalystbiosciences.com






20

MAA-102 Study Design

IPK assessment of intravenous (IV) and subcutaneous (SC) MarzAA




Primary:

Evaluate the pharmacokinetics (PK) + of ascending subcutaneous (SC) doses of MarzAA

Secondary:

- + Determine if PK behaves in a dose proportional manner + Determine whether a split injection provides the same
- PK as a single injection
- + Determine the pharmacodynamics (PD) of SC MarzAA
- + Evaluate the safety of SC MarzAA




Marzeptacog alfa (activated) program

Moving forward in clinical development to address key unmet needs

- Robust SQ prophylaxis clinical efficacy demonstrated
- Safe and well tolerated
- No anti-drug antibodies detected

Pivotal trial guidance obtained from EMA & MHRA







- PK study initiated to assess range of clinical doses
- Exploring the use of SQ MarzAA in treatment of a bleed
- Preparing for End of Phase 2 meeting 4Q 2019
- Moving forward with Phase 3 study planning

The new standard in hemophilia B prophylaxis

Patients in high mild range are protected from spontaneous bleeds



- Our concept of prophylactic treatment is to keep severe & moderate +hemophilia patients in the high mild range
- Subcutaneous factor treatments build up over time, offering long-term + stability in clotting levels




Dalcinonacog alfa – DalcA

Novel clinical stage SQ FIX product candidate differentiated from IV market leaders

Phase 1/2 completed

- + 22-fold more potent than BeneFIX in man
- + Allows subcutaneous dosing
- + Half-life prolonged when using subcutaneous dosing
- + Maintains continuous protective FIX activity levels of 12 30%
- + Disruptive to all intravenous products

Orphan Drug Designation in US & EU



R318Y Resistance to antithrombin


T343R


R338E

Increased FVIIIa affinity & procoagulant activity

Dalcinonacog phase 1/2 open label design

Hemophilia B FIX






*First SQ dose 30 min post-IV

SQ DalcA PK increases half-life by 3.6 fold over IV

Cohort 2 & 3: PK activity profiles after IV and SQ Dalcinonacog alfa administration


Route		t-half alpha (hrs)	t-half beta (hrs)	Tmax	AUC 0-t (mU/mL*hr)	Bioavailability
IV	Mean ± SD	9.4 ± 4.4	27.0 ± 2.2	16.7 ±11.3 mins	1026 ± 330	
	Median [25%-75%]	9.4 [6.4-13.2]	27.6 [26.4-29.2]	15 mins [5-30]	945 [780-1265]	
	Mean ± SD		242.2 ± 365.5	29.0 ± 16.3 h	306 ± 148	19.8 ± 5.2%
SQ	Median [25%-75%]	3.4 (n=1)	98.7 [60.0-369.4]	24 h [19.5-48]	352 [138-410]	18.5% [15.4-24.7%]






DalcA Phase 1/2 clinical trial FIX activity results

Trough levels >12% are sufficient to protect against spontaneous joint bleeds







Conclusions on the dalcinonacog alfa program

Continuing clinical development after an extensive immunogenicity risk assessment


Preclinical immunogenicity assessment showed that dalcinonacog alfa is equivalent to that of competitors such as BeneFIX

A comprehensive evaluation of the drug product showed comparable quality to marketed rFIX products

KoLs and subject experts agree with the immunogenicity risk assessment and proceeding with the P2b to evaluate the safety and efficacy of dalcinonacog alfa


catalystbiosciences.com






Dalcinonacog alfa phase 2b SQ clinical trial design

DLZ-201 enrolling






Dalcinonacog alfa program

Moving forward in clinical development to address key unmet needs







- Two anti-drug antibodies detected but low risk of immunogenicity
 - Expected Top line Phase 2 results 4Q 2019

Addressing unmet needs in orphan bleeding disorders

Hemophilia A with inhibitors

Anti-FVIII antibodies that neutralize activity

- 30% of Hem A patients
- Treatments: SQ Hemlibra[®], IV FVIIa, FEIBA[®]

SQ treatment of bleeds & Hemlibra non-responders

Hemophilia B with inhibitors

Anti-FIX antibodies that neutralize activity

- 5% of Hem B patients
- Treatments: IV FVIIa, FEIBA

SQ prophylaxis & SQ treatment of bleeds


Factor VII deficiency – Glanzmann Thrombasthenia

Congenital lack of FVII – Platelet abnormality


- Treatments: IV plasma FVII or FVIIa

SQ prophylaxis in severe patients & SQ treatment of bleeds

MarzAA & DalcA



catalystbiosciences.com



Hemophilia B

Congenital lack of functional FIX

- Treated with IV FIX products

SQ prophylaxis

Hemophilia A

- Congenital lack of functional FVIII
- Treatments: IV FVIII or SQ Hemlibra
- SQ treatment of bleed

Acquired Hemophilia

Rare disorder, caused by anti-FVIII nAbs

Treated with immunosuppressants +
 IV FVIIa, FEIBA or Obizur[®]

SQ treatment of bleeds & SQ prevention of re-bleeds

THANK YOU

